These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3863701)

  • 1. Correlations between anthracycline resistance, drug accumulation and membrane glycoprotein patterns in solid tumors of mice.
    Kessel D; Corbett T
    Cancer Lett; 1985 Sep; 28(2):187-93. PubMed ID: 3863701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modes of resistance to anthracyclines and other natural products.
    Kessel D; Romine M; Decker D
    Prog Clin Biol Res; 1986; 223():81-93. PubMed ID: 3543948
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical mechanism for resistance to anthracycline antibiotics.
    Inaba M
    Prog Clin Biol Res; 1986; 223():35-44. PubMed ID: 3468518
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
    Gupta S; Patel K; Singh H; Gollapudi S
    Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular pharmacology of anthracycline resistance and its circumvention.
    Tapiero H; Fourcade A; Munck JN; Zwingelstein G; Lampidis TJ
    Drugs Exp Clin Res; 1986; 12(1-3):265-73. PubMed ID: 3460753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.
    Hill BT; Dennis LY; Li XT; Whelan RD
    Cancer Chemother Pharmacol; 1985; 14(3):194-201. PubMed ID: 3858013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and metabolism of adriamycin in mice. Comparison with daunomycin.
    Di Fronzo G; Gambetta RA; Lenaz L
    Rev Eur Etud Clin Biol; 1971; 16(6):572-6. PubMed ID: 5125106
    [No Abstract]   [Full Text] [Related]  

  • 8. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.
    Kessel D; Wilberding C
    Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of an anthracycline-resistant human leukemic cell line.
    Bhalla K; Hindenburg A; Taub RN; Grant S
    Cancer Res; 1985 Aug; 45(8):3657-62. PubMed ID: 3860286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tunicamycin on anthracycline resistance in P388 murine leukemia cells.
    Chou TH; Kessel D
    Biochem Pharmacol; 1981 Nov; 30(22):3134-6. PubMed ID: 6950722
    [No Abstract]   [Full Text] [Related]  

  • 12. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
    Demant EJ; Sehested M; Jensen PB
    Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of action of calcium antagonists which alter anthracycline resistance.
    Kessel D; Wilberding C
    Biochem Pharmacol; 1984 Apr; 33(7):1157-60. PubMed ID: 6585204
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m-AMSA as a probe for transport phenomena associated with anthracycline resistance.
    Kessel D; Wheeler C
    Biochem Pharmacol; 1984 Apr; 33(7):991-3. PubMed ID: 6585205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro studies on anthracycline haloderivatives.
    Facchinetti T; Geroni C; Fumagalli A; Giuliani FC
    Drugs Exp Clin Res; 1986; 12(8):657-61. PubMed ID: 3463498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.
    Skovsgaard T
    Eur J Haematol Suppl; 1987; 47():7-20. PubMed ID: 3552720
    [No Abstract]   [Full Text] [Related]  

  • 18. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between calcium antagonists, calcium fluxes and anthracycline transport.
    Kessel D; Wilberding C
    Cancer Lett; 1984 Nov; 25(1):97-101. PubMed ID: 6097354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
    Friche E; Demant EJ; Sehested M; Nissen NI
    Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.